NCT05460169View on ClinicalTrials.gov

Renal Denervation in ADPKD- RDN-ADPKD Study

NAActive, not recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 14, 2022

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions
Uncontrolled HypertensionAutosomal Dominant Polycystic Kidney DiseaseRenal Denervation
Interventions
DEVICE

Renal denervation

The Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark. The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.

Trial Locations (1)

91054

University Hospital FAU Erlangen-Nürnberg, Erlangen

All Listed Sponsors
lead

University of Erlangen-Nürnberg Medical School

OTHER